Bolt Biotherapeutics (BOLT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Bolt Biotherapeutics stock (BOLT) is currently trading at $4.29. Bolt Biotherapeutics PS ratio (Price-to-Sales) is 1.19. Analyst consensus price target for BOLT is $29.00. WallStSmart rates BOLT as Sell.
- BOLT PE ratio analysis and historical PE chart
- BOLT PS ratio (Price-to-Sales) history and trend
- BOLT intrinsic value — DCF, Graham Number, EPV models
- BOLT stock price prediction 2025 2026 2027 2028 2029 2030
- BOLT fair value vs current price
- BOLT insider transactions and insider buying
- Is BOLT undervalued or overvalued?
- Bolt Biotherapeutics financial analysis — revenue, earnings, cash flow
- BOLT Piotroski F-Score and Altman Z-Score
- BOLT analyst price target and Smart Rating
Bolt Biotherapeutics
📊 No data available
Try selecting a different time range
Smart Analysis
Bolt Biotherapeutics (BOLT) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Bolt Biotherapeutics (BOLT) Key Strengths (3)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 90.10% year-over-year
Paying $1.19 for every $1 of annual revenue
Supporting Valuation Data
Bolt Biotherapeutics (BOLT) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Bolt Biotherapeutics (BOLT) Detailed Analysis Report
Overall Assessment
This company scores 38/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 9.3/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth, Price/Sales. Valuation metrics including Price/Sales (1.19), Price/Book (0.34) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 90.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Market Cap. Profitability pressure is visible in Return on Equity at -79.70%, Operating Margin at -224.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -79.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 90.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BOLT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BOLT's Price-to-Sales ratio of 1.19x trades 19% below its historical average of 1.47x (14th percentile). The current valuation is 31% below its historical high of 1.71x set in Feb 2026, and 7% above its historical low of 1.11x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~1.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Bolt Biotherapeutics (BOLT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Bolt Biotherapeutics is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 8M with 90% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 90% YoY, reaching 8M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 65% of revenue (5M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Bolt Biotherapeutics maintain 90%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Bolt Biotherapeutics.
Bottom Line
Bolt Biotherapeutics is a high-conviction growth story with revenue accelerating at 90% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Bolt Biotherapeutics(BOLT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the discovery, development and commercialization of pharmaceutical products. The company is headquartered in Redwood city, California.